Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Debt
Short-term and long-term borrowings combined.
Helix BioPharma Corp.TSX: HBP.TO
Total Debt · Q3 FY2026 · quarter ended Apr 2026
Total debt remains negative
Q3 FY2026 total debt was CA$359K, compared with CA$0 a year earlier. Over 3 fiscal years it compounded at -48.6% a year.
Context
- Total debt amounted to 1.7% of total assets at the end of Q3 FY2026, up 1.7 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
CAD · from the balance sheet
- Latest · FY2025
- 335K CAD
- Year-over-year change
- —
- 4-year CAGR
- -44.8%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 335K | — |
| FY2024 | 2024-07-31 | 0 | — |
| FY2023 | 2023-07-31 | 0 | -100.0% |
| FY2022 | 2022-07-31 | 2.47M | -31.7% |
| FY2021 | 2021-07-31 | 3.61M | — |
Total Debt vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 1.7% of total assets for HBP.TO, versus a peer median of 16.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $43.96M USD | -31.0% | -20.1% | 33.5% | |
| Apr 2026 | CA$2.45M CAD | -48.2% | +297.1% | 159.9% | |
| Apr 2026 | CA$359K CAD | — | -48.6% | 1.7% | |
| Mar 2026 | CA$116.41K CAD | -22.7% | +19.9% | 0.4% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding HBP.TO) | — | -31.0% | +19.9% | 16.9% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.